These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33651280)

  • 1. Health state utility and quality of life measures in patients with chronic myeloid leukemia in France.
    S F; P CM; A GB; M D; R K; P TB; J B
    Qual Life Res; 2021 Jul; 30(7):2021-2032. PubMed ID: 33651280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24.
    Efficace F; Baccarani M; Breccia M; Saussele S; Abel G; Caocci G; Guilhot F; Cocks K; Naeem A; Sprangers M; Oerlemans S; Chie W; Castagnetti F; Bombaci F; Sharf G; Cardoni A; Noens L; Pallua S; Salvucci M; Nicolatou-Galitis O; Rosti G; Mandelli F
    Qual Life Res; 2014 Apr; 23(3):825-36. PubMed ID: 24026634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of Life and Symptom Burden With First- and Second-generation Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myeloid Leukemia.
    Bostan H; Toptas T; Tanrikulu FP; Kut K; Arikan F; Yilmaz F; Atagunduz I; Firatli-Tuglular T
    Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):836-842. PubMed ID: 32958432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia.
    Efficace F; Iurlo A; Patriarca A; Stagno F; Bee PC; Ector G; Capodanno I; Elena C; Bonifacio M; Blijlevens NMA; Caocci G; Wan C; Abruzzese E; Breccia M; Cottone F; Okumura I; Oerlemans S; Cascavilla N; Albano F; Kota V; Sztankay M; Miggiano MC; Saussele S; Di Renzo N; Sorà F; Castagnetti F; Baccarani M; Vignetti M; Rosti G
    Leuk Lymphoma; 2021 Mar; 62(3):669-678. PubMed ID: 33153355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life among chronic myeloid leukemia patients in the second-line treatment with nilotinib and influential factors.
    Nguyen CTT; Nguyen BT; Nguyen TTT; Petrelli F; Scuri S; Grappasonni I
    Qual Life Res; 2022 Mar; 31(3):733-743. PubMed ID: 34258697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.
    Efficace F; Castagnetti F; Martino B; Breccia M; D'Adda M; Angelucci E; Stagno F; Cottone F; Malato A; Trabacchi E; Capalbo SF; Gobbi M; Visani G; Salvucci M; Capodanno I; Tosi P; Tiribelli M; Scortechini AR; Levato L; Maino E; Binotto G; Gugliotta G; Vignetti M; Baccarani M; Rosti G
    Cancer; 2018 May; 124(10):2228-2237. PubMed ID: 29499087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-Related Quality of Life of Patients with Chronic Myeloid Leukemia as Measured by Patient-Reported Outcomes: Current State and Future Directions.
    Schoenbeck KL; Flynn KE
    Curr Hematol Malig Rep; 2021 Dec; 16(6):491-499. PubMed ID: 34648119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of symptom burden on patient quality of life in chronic myeloid leukemia.
    Cella D; Nowinski CJ; Frankfurt O
    Oncology; 2014; 87(3):133-47. PubMed ID: 25012261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of CML using IFN-alpha: impact on quality of life.
    Homewood J; Watson M; Richards SM; Halsey J; Shepherd PC;
    Hematol J; 2003; 4(4):253-62. PubMed ID: 12872150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure.
    Whiteley J; Reisman A; Shapiro M; Cortes J; Cella D
    Curr Med Res Opin; 2016 Aug; 32(8):1325-34. PubMed ID: 27045164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group.
    Efficace F; Breccia M; Saussele S; Kossak-Roth U; Cardoni A; Caocci G; Chie W; Naeem A; Nicolatou-Galitis O; Cocks K; Vignetti M; Baccarani M; Mandelli F; Sprangers M
    Ann Hematol; 2012 Sep; 91(9):1371-81. PubMed ID: 22543826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer.
    Marriott ER; van Hazel G; Gibbs P; Hatswell AJ
    J Med Econ; 2017 Feb; 20(2):193-199. PubMed ID: 27676291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib.
    Efficace F; Baccarani M; Breccia M; Cottone F; Alimena G; Deliliers GL; Baratè C; Specchia G; Di Lorenzo R; Luciano L; Turri D; Martino B; Stagno F; Dabusti M; Bergamaschi M; Leoni P; Simula MP; Levato L; Fava C; Veneri D; Sica S; Rambaldi A; Rosti G; Vignetti M; Mandelli F
    Leukemia; 2013 Jul; 27(7):1511-9. PubMed ID: 23417029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The European Organisation for Research and Treatment of Cancer Quality of Life Utility-Core 10 Dimensions: Development and Investigation of General Population Utility Norms for Canada, France, Germany, Italy, Poland, and the United Kingdom.
    Pilz MJ; Nolte S; Liegl G; King M; Norman R; McTaggart-Cowan H; Bottomley A; Rose M; Kemmler G; Holzner B; Gamper EM;
    Value Health; 2023 May; 26(5):760-767. PubMed ID: 36572102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Converting EORTC QLQ-C30 scores to utility scores in the brigatinib ALTA study.
    Kawata AK; Lenderking WR; Eseyin OR; Kerstein D; Huang J; Huang H; Zhang P; Lin HM
    J Med Econ; 2019 Sep; 22(9):924-935. PubMed ID: 31125274
    [No Abstract]   [Full Text] [Related]  

  • 16. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population.
    Efficace F; Baccarani M; Breccia M; Alimena G; Rosti G; Cottone F; Deliliers GL; Baratè C; Rossi AR; Fioritoni G; Luciano L; Turri D; Martino B; Di Raimondo F; Dabusti M; Bergamaschi M; Leoni P; Simula MP; Levato L; Ulisciani S; Veneri D; Sica S; Rambaldi A; Vignetti M; Mandelli F;
    Blood; 2011 Oct; 118(17):4554-60. PubMed ID: 21750313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of new generic formulations of imatinib mesylate on general quality of life in chronic phase chronic myeloid leukaemia patients.
    Uyanik MS; Pamuk GE; Maden M; Merev E; Cevik G; Uyanik V; Umit EG; Demir AM; Akker M
    Eur J Cancer Care (Engl); 2017 Mar; 26(2):. PubMed ID: 26594025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy.
    Kantarjian HM; Mamolo CM; Gambacorti-Passerini C; Cortes JE; Brümmendorf TH; Su Y; Reisman AL; Shapiro M; Lipton JH
    Cancer; 2018 Feb; 124(3):587-595. PubMed ID: 29072772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Single Center Survey of Health-Related Quality of Life among Acute Myeloid Leukemia Survivors in First Complete Remission.
    Cheng MJ; Smith BD; Hourigan CS; Gojo I; Pratz KW; Blackford AL; Mehta AK; Smith TJ
    J Palliat Med; 2017 Nov; 20(11):1267-1273. PubMed ID: 28537498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of a medication management service in improving adherence to tyrosine kinase inhibitors and clinical outcomes of patients with chronic myeloid leukaemia: a randomised controlled trial.
    Tan BK; Chua SS; Chen LC; Chang KM; Balashanker S; Bee PC
    Support Care Cancer; 2020 Jul; 28(7):3237-3247. PubMed ID: 31734798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.